Clinical trials: Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
This pilot phase I trial studies the side effects of durvalumab and tremelimumab in treating patients with muscle-invasive, high-risk urothelial cancer that cannot be treated with cisplatin-based therapy before surgery.
- Conditions
- Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
- Trial name
- NCT02812420
- Testing
- Durvalumab, Therapeutic Conventional Surgery, Tremelimumab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center